公开(公告)号：US20240245663A1

公开(公告)日：2024-07-25

申请号：US18623761

申请日：2024-04-01

申请人： Lumos Pharma, Inc.

发明人： Alpa B. Parikh ,  John C. McKew

IPC分类号： A61K31/438 ,  A61K9/20 ,  A61K9/28 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

CPC分类号： A61K31/438 ,  A61K9/2077 ,  A61K9/2846 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

摘要： The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.

公开(公告)号：US11884646B2

公开(公告)日：2024-01-30

申请号：US17688016

申请日：2022-03-07

申请人： Helsinn Healthcare SA

发明人： Silvina Garcia Rubio ,  Mauro Perseghini ,  Angelo Guainazzi ,  Claudio Pietra ,  Claudio Giuliano

IPC分类号： C07D401/12 ,  A61P5/06

CPC分类号： C07D401/12 ,  A61P5/06 ,  C07B2200/13

摘要： Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.

公开(公告)号：US11744837B2

公开(公告)日：2023-09-05

申请号：US16945599

申请日：2020-07-31

申请人： Corcept Therapeutics, Inc.

发明人： Andreas Moraitis

IPC分类号： A61K31/567 ,  A61P5/10 ,  A61P3/10 ,  A61P5/06 ,  G01N33/74 ,  A61K45/06

CPC分类号： A61K31/567 ,  A61P3/10 ,  A61P5/06 ,  A61P5/10 ,  G01N33/743 ,  A61K45/06

摘要： This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.

公开(公告)号：US20220233630A1

公开(公告)日：2022-07-28

申请号：US17721725

申请日：2022-04-15

申请人： Amryt Endo, Inc.

发明人： Roni MAMLUK ,  Sam Teichman

IPC分类号： A61K38/08 ,  A61K38/31 ,  A61K9/48 ,  A61P5/06 ,  A61K9/00

摘要： Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

公开(公告)号：US20200299260A1

公开(公告)日：2020-09-24

申请号：US16767842

申请日：2018-12-07

申请人： Helsinn Healthcare SA

发明人： Silvina GARCIA RUBIO ,  Mauro PERSEGHINI ,  Angelo GUAINAZZI ,  Claudio PIETRA ,  Claudio GIULIANO

IPC分类号： C07D401/12 ,  A61P5/06

摘要： Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.

公开(公告)号：US20200247872A1

公开(公告)日：2020-08-06

申请号：US16846003

申请日：2020-04-10

申请人： JCR Pharmaceuticals Co., Ltd.

发明人： Kenichi TAKAHASHI ,  Aya YOSHIOKA ,  Hideto MORIMOTO ,  Masafumi KINOSHITA

IPC分类号： C07K14/765 ,  A61K38/00 ,  C12N5/16 ,  C07K19/00 ,  C12N15/09 ,  A61P43/00 ,  A61P3/00 ,  A61P5/06 ,  C07K14/61

摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.

公开(公告)号：US10660938B2

公开(公告)日：2020-05-26

申请号：US15566657

申请日：2016-04-15

申请人： FERRING B.V.

发明人： Joan Carles Arce Saez ,  Lisbeth Helmgaard ,  Bjarke Mirner Klein

IPC分类号： A61K38/24 ,  A61P5/24 ,  A61P5/06

摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.

公开(公告)号：US10464984B2

公开(公告)日：2019-11-05

申请号：US15566961

申请日：2016-04-22

申请人： FERRING B.V.

发明人： Daniel Plaksin ,  Ayelet Grinhut

IPC分类号： C07K14/59 ,  C12N9/10 ,  A61K38/16 ,  C12N15/63 ,  A61P5/06

摘要： A host cell characterized in that it comprises integrated into its genome a sequence coding for the a chain of hCG, and use of the host cell to produce recombinant hCG.

公开(公告)号：US20180371080A1

公开(公告)日：2018-12-27

申请号：US15987766

申请日：2018-05-23

申请人： NGM Biopharmaceuticals, Inc.

发明人： Daniel David Kaplan ,  Xuecai Ge ,  Hui Tian

IPC分类号： C07K16/26 ,  A61P3/04 ,  A61P3/10 ,  A61P5/06

摘要： The present disclosure provides binding agents that modulate the interaction between LEAP2 and GHSR. Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use, to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes.

公开(公告)号：US20180127478A1

公开(公告)日：2018-05-10

申请号：US15706538

申请日：2017-09-15

申请人： Wei-Chiang Shen ,  Li Zhou ,  Jennica Zaro

发明人： Wei-Chiang Shen ,  Li Zhou ,  Jennica Zaro

IPC分类号： C07K14/61 ,  A61P5/06

CPC分类号： C07K14/61 ,  A61K38/00 ,  A61P5/06 ,  C07K2319/30

摘要： Disclosed herein is a recombinant polypeptide comprising two single chain Fc domains fused or covalently attached to each other by a peptide linker, with the proviso that the peptide linker does not comprise an antibody hinge domain (also referred to herein as an “sc(Fc)2 construct”). In a further aspect, the recombinant polypeptide also comprises, or alternatively consists essentially of, or yet further consists of a first therapeutic moiety. Methods for use of the polypeptides, as well as methods for making same, are provided herein.